Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 9/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.68 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | CCR6 | P51684 | 2/20 | 0.50 |
| ▸ | PHGDH | O43175 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | USP5 | P45974 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4814338 | 0.88 | HDAC3 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4022511 | 0.81 | HDAC1 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL974223 | 0.77 | SMN1; SMN2 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12933234 | 0.76 | CCR6 (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12933244 | 0.75 | CCR6 (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4018579 | 0.73 | HDAC1 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12933235 | 0.73 | CCR6 (0.63) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14164233 | 0.73 | HDAC6 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL976579 | 0.73 | L3MBTL1 (0.53) | — | |
| SCHEMBL4292404 | 0.72 | HDAC2 (0.83) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139535-A1 | INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS | 2008-06-12 | — | — | US | claimed |
| US-7345043-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS (US) | 2008-03-18 | — | — | US | claimed |
| US-20050234033-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS | 2005-10-20 | — | — | US | claimed |
| US-20080139535-A1 | INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS | 2008-06-12 | — | — | US | disclosed |
| US-20080139535-A1 | INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS | 2008-06-12 | — | — | US | disclosed |
| US-7345043-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345043-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS (US) | 2008-03-18 | — | — | US | disclosed |
| US-20050234033-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139535-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC10 | HDAC3 6/4885HDAC4 11/4885HDAC1 1/4885 |
| US-20050234033-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | HDAC3 6/4885HDAC4 11/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.